Blog

Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC

Carlos Barrios/lacogcancerresearch.org

May 15, 2025, 14:51

Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC

Pablo Mando, Editor-in-Chief of Oncologia Clínica, shared a post on X:

“Great presentation by Carlos Barrios reporting that T-DXd demonstrated a clinically meaningful efficacy benefit over both TPC subgroups (capecitabine and taxane), with improved PFS, ORR, DOR, and PFS2 in DB-06.”

Paolo Tarantino, Advanced Research Fellowship at Dana-Farber Cancer Institute and Harvard Medical School, reshared the post on X, adding:

“Seems to confirm a frequent empirical finding:

capecitabine > taxanes for treating HR+/HER2- MBC (with T-DXd outperforming both).”

More posts featuring Paolo Tarantino.

cancer capecitabine Dana-Farber Cancer Institute DB-06 DOR fight against cancer Global fight against cancer Harvard Medical School MBC metastatic breast cancer OncoDaily Oncologia Clínica Oncology ORR pablo mando Paolo Tarantino PFS PFS2 T-Dxd taxane

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research